Tolvaptan in patients with autosomal dominant polycystic kidney disease
| Data(s) |
20/12/2012
|
|---|---|
| Resumo |
The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function. |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Torres , V E , Chapman , A B , Devuyst , O , Gansevoort , R T , Grantham , J J , Higashihara , E , Perrone , R D , Krasa , H B , Ouyang , J , Czerwiec , F S , TEMPO 3:4 Trial Investigators & Maxwell , A 2012 , ' Tolvaptan in patients with autosomal dominant polycystic kidney disease ' New England Journal of Medicine , vol 367 , no. 25 , pp. 2407-18 . DOI: 10.1056/NEJMoa1205511 |
| Palavras-Chave | #Adolescent #Adult #Benzazepines #Double-Blind Method #Female #Glomerular Filtration Rate #Humans #Kidney #Male #Middle Aged #Organ Size #Polycystic Kidney, Autosomal Dominant #Receptors, Vasopressin #Sodium #Young Adult |
| Tipo |
article |
